BioSpace News Archive

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced the grant of inducement awards to two new employees.

Samantha Castellanos-Santana was delivered at 30 weeks gestation and was born with an opening in her heart, a condition known as patent ductus arteriosus.

Today, the U.S. Food and Drug Administration authorized the first diagnostic test for at home collection of patient samples to detect both COVID-19 and influenza A and B (flu). The FDA authorized Quest Diagnostics RC COVID-19 +Flu RT-PCR Test for prescription use with the Quest Diagnostics Self-Collection Kit for COVID-19 +Flu

Biocom California, the association representing the California life science industry, joined the Biotechnology Innovation Organization and the California Life Sciences Association in filing a challenge against the Department of Health and Human Services’ recent Most-Favored Nation Interim Final Rule.

While multiple research studies show that Black and Hispanic patients are more likely to test positive for COVID-19, a team of investigators at NYU Langone Health has found that once hospitalized, Black patients (after controlling for other serious health conditions and neighborhood income) were less likely to have severe illness, die, or be discharged to hospice compared to White patients.

Neurelis, Inc., announced today the company has 12 posters being presented at the American Epilepsy Society Annual Meeting being held virtually from December 4 through December 8.

Vizient, Inc. submitted comments to the Food and Drug Administration (FDA) today applauding the agency’s efforts to publish a list of essential medicines, medical countermeasures and critical inputs to help prepare for the next potential public health emergency

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today the closing of an underwritten public offering of 5,513,699 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 719,178 shares,

Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company approved the grant of equity awards to two new employees with grant date of December 1, 2020, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan (but under the terms of the 2020 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment

Aspen Dental has officially opened its doors in Wichita, Kansas with the opening of a brand-new office, bringing two new local dentists to their community.